Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Ter Heine

Showing results (91-100 of 160) with videos related to

Pageof 16
Sort By:
Clinical Pharmacokinetics|October 19, 2023
Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in TreatmentLeila S Otten, Berber Piet, Demy van den Haak, et al.
Cancers|December 23, 2022
High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid TumorsSophie L Gerritse, Mariette Labots, Rob Ter Heine, et al.
European Journal of Clinical Pharmacology|August 16, 2003
Incidence and risk factors for nevirapine-associated rashMonique M R de Maat, Rob ter Heine, Jan W Mulder, et al.
Clinical Pharmacology and Therapeutics|January 20, 2022
The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung CancerNikki de Rouw, Merel de Boer, René J Boosman, et al.
Clinical Pharmacokinetics|January 9, 2021
Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic AnalysisNikki de Rouw, Rene J Boosman, Alwin D R Huitema, et al.
British Journal of Clinical Pharmacology|January 29, 2021
The potential of individualized dosing of ravulizumab to improve patient-friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costsMendy Ter Avest, Saskia M C Langemeijer, Saskia E M Schols, et al.
The Journal of Antimicrobial Chemotherapy|January 17, 2019
Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adultsRoeland E Wasmann, Cornelis Smit, Rob Ter Heine, et al.
Pediatric Nephrology (Berlin, Germany)|February 3, 2025
Model-informed repurposing of eliglustat for treatment and prophylaxis of Shiga toxin-producing Escherichia coli hemolytic-uremic syndrome (STEC-HUS) in childrenDavid F G J Wolthuis, Jolien J M Freriksen, Mendy Ter Avest, et al.
Clinical Pharmacology and Therapeutics|April 17, 2020
Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen SusceptibilityEmilie M Gieling, Eveline Wallenburg, Tim Frenzel, et al.
Clinical Pharmacokinetics|July 29, 2020
Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant RecipientsTom C Zwart, Dirk Jan A R Moes, Paul J M van der Boog, et al.
Pageof 16

Showing results (91-100 of 160) with videos related to

Sort By:
Pageof 16
Clinical Pharmacokinetics|October 19, 2023
Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in TreatmentLeila S Otten, Berber Piet, Demy van den Haak, et al.
Cancers|December 23, 2022
High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid TumorsSophie L Gerritse, Mariette Labots, Rob Ter Heine, et al.
European Journal of Clinical Pharmacology|August 16, 2003
Incidence and risk factors for nevirapine-associated rashMonique M R de Maat, Rob ter Heine, Jan W Mulder, et al.
Clinical Pharmacology and Therapeutics|January 20, 2022
The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung CancerNikki de Rouw, Merel de Boer, René J Boosman, et al.
Clinical Pharmacokinetics|January 9, 2021
Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic AnalysisNikki de Rouw, Rene J Boosman, Alwin D R Huitema, et al.
British Journal of Clinical Pharmacology|January 29, 2021
The potential of individualized dosing of ravulizumab to improve patient-friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costsMendy Ter Avest, Saskia M C Langemeijer, Saskia E M Schols, et al.
The Journal of Antimicrobial Chemotherapy|January 17, 2019
Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adultsRoeland E Wasmann, Cornelis Smit, Rob Ter Heine, et al.
Pediatric Nephrology (Berlin, Germany)|February 3, 2025
Model-informed repurposing of eliglustat for treatment and prophylaxis of Shiga toxin-producing Escherichia coli hemolytic-uremic syndrome (STEC-HUS) in childrenDavid F G J Wolthuis, Jolien J M Freriksen, Mendy Ter Avest, et al.
Clinical Pharmacology and Therapeutics|April 17, 2020
Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen SusceptibilityEmilie M Gieling, Eveline Wallenburg, Tim Frenzel, et al.
Clinical Pharmacokinetics|July 29, 2020
Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant RecipientsTom C Zwart, Dirk Jan A R Moes, Paul J M van der Boog, et al.
Pageof 16